180
Participants
Start Date
February 29, 2024
Primary Completion Date
August 31, 2025
Study Completion Date
September 30, 2025
AK0529
Active Substance: AK0529, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral
Placebo
Active Substance: Placebo, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral
RECRUITING
Beijing Children's Hospital, Capital Medical University, Beijing
RECRUITING
Beijing Children's Hospital, Capital Medical University, Beijing
RECRUITING
First Hospital of Jilin University, Changchun
RECRUITING
Hunan Provincial People's Hospital, Changsha
RECRUITING
West China Second University Hospital, Sichuan University, Chengdu
RECRUITING
Children's Hospital, Zhejiang University School of Medicine, Hangzhou
RECRUITING
Sanya Central Hospital, Hainan Third People's Hospital, Sanya
RECRUITING
Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai
RECRUITING
Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai
RECRUITING
Shengjing Hospital of China Medical University, Shenyang
RECRUITING
Tianjin Children's Hospital（Longyan）, Tianjin
RECRUITING
Tianjin Children's Hospital（Machang）, Tianjin
RECRUITING
Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou
RECRUITING
Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
RECRUITING
Wuxi Children's Hospital, Wuxi
RECRUITING
First Affiliated Hospital of Xiamen University, Xiamen
RECRUITING
Women and Children's Hospital, and the School of Medicine, Xiamen University, Xiamen
RECRUITING
Zhongshan Women and Children's Hospital-Zhongshan Boai Hospital, Zhongshan
Shanghai Ark Biopharmaceutical Co., Ltd.
INDUSTRY